人表皮生长因子受体2低表达乳腺癌的研究进展

Progress of breast cancer with low expression of human epidermal growth factor receptor 2

近年来人表皮生长因子受体2(HER2)是乳腺癌研究的重要靶点,以曲妥珠单抗为代表的靶向药物极大地改善了HER2阳性乳腺癌患者的预后。德曲妥珠单抗(T-DXd)等抗体药物偶联物(ADC)在HER2低表达乳腺癌中取得的显著疗效,使HER2低表达乳腺癌逐渐成为研究热点。随着研究的不断深入,对HER2的检测、乳腺癌的分子分型均提出新的观点及看法,亦有学者提出HER2超低表达的概念。多种ADC及新型治疗模式在HER2低表达乳腺癌中的应用正在不断探索中。文章对HER2低表达乳腺癌的定义、检测及判定、临床病理特征以及治疗进展情况进行综述。

Human epidermal growth factor receptor 2(HER2)is an important therapeutic target for breast cancer in recent years.The emergence of targeted drugs represented as trastuzumab has drastically improved the prognosis of HER2-positive breast cancer patients.Antibody-drug conjugates(ADC)such as trastuzumab deruxtecan(T-DXd)have shown the obvious therapeutic efficacies in breast cancer with HER2 low expression recently,which has become a research hotpot.With the deepening of the research,new views of the detection of HER2 and the molecular subtypes of breast cancer are proposed,besides,the concept of ultra-low HER2 expression is also proposed by some scholars.Several studies have explored the application of ADC and new treatments in HER2 low expression breast cancer.This paper reviews the definition,the detection and determination,clinicopathologic characteristics and treatment progress of breast cancer with HER2 low expression.